Pharmaceuticals News and Research

RSS

Mallinckrodt launches OptiSync system to help healthcare professionals manage radiology data

Mallinckrodt today announced the U.S. launch of the OptiSync data management system as a new technology in its Global Medical Imaging segment.

23 Sep 2014

Yale University researchers study potential new treatment to reverse effects of pulmonary fibrosis

Yale University researchers are studying a potential new treatment that reverses the effects of pulmonary fibrosis, a respiratory disease in which scars develop in the lungs and severely hamper breathing.

23 Sep 2014

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Elusys Therapeutics, Inc., a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced it has completed three phase 3 healthy adult volunteer safety studies of obiltoxaximab (ETI-204).

23 Sep 2014

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Avalon Ventures today announced the launch of two new companies formed through its collaboration with GlaxoSmithKline to fund and launch up to 10 early-stage life science companies.

23 Sep 2014

C-Path renews grant to advance more effective drug treatments for TB

The Critical Path Institute, an independent, non-profit organization that works to accelerate the speed of drug and medical product development, today announced it has received a three-year grant renewal from the Bill & Melinda Gates Foundation.

22 Sep 2014

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA (aflibercept) Injection for myopic choroidal neovascularization (myopic CNV).

22 Sep 2014

Demand for $84,000 hepatitis C drug slows

Health care providers may be waiting for other, soon-to-be-released drugs to treat hepatitis C. Also, an Indian pharmaceutical company faces Justice Department questions on pricing data for Medicaid.

19 Sep 2014

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

19 Sep 2014

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today it has initiated its ATHENA natural history of disease study in patients with Alport syndrome, a life-threatening genetic kidney disease with no approved therapy.

19 Sep 2014

PCI acquires Biotec Services International

PCI is pleased to announce it has acquired Biotec Services International. Biotec is a leading provider of Clinical Trial Services and Temperature Controlled Pharmaceutical Services headquartered in Bridgend, Wales in the United Kingdom.

19 Sep 2014

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).

18 Sep 2014

Disrupting cancer regulator MYC: an interview with Professor Kim Janda

MYC is an oncogenic member of the basic helix-loop-helix-leucine zipper transcription factor family. In its monomeric form, MYC’s tertiary structure is intrinsically disordered and the protein is transcriptionally inactive.

17 Sep 2014

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

Isis Pharmaceuticals, Inc. announced that it has earned a $4 million milestone payment from Achaogen, Inc. associated with the initiation of a Phase 3 study of plazomicin in patients with serious multi-drug resistant (MDR), gram-negative bacterial infections.

17 Sep 2014

UMass Amherst doctoral student in chemistry receives USP's 2014-15 Global Fellowship Award

University of Massachusetts Amherst doctoral student in chemistry Khaja Muneeruddin is one of three promising young scientists to recently receive the 2014-15 Global Fellowship Award from the United States Pharmacopeial Convention, dual publishers of the official pharmacopeia and National Formulary (NF), the book of directions for identifying compound medicines.

17 Sep 2014

EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that, together with the Asbestos Disease Research Institute, it has received the 2014 Cancer Institute New South Wales Premier’s Award for Excellence in Translational Cancer Research.

17 Sep 2014

Stago receives FDA approval for automated, highly sensitive D-dimer test

Stago has received approval from the US Food and Drug Administration for the reagent STA -Liatest D-Di, in the exclusion of pulmonary embolism (PE) in patients with low or moderate risk, presenting at an emergency unit.

17 Sep 2014

NIH awards grant to scientist to link drugs, genes and diseases

The National Institutes of Health wants to make the process of finding new drugs faster and better. The effort will help all 27 of its research institutes and centers. So, the nation's medical research agency awarded Tudor Oprea, MD, PhD, a 2-year $4.9 million grant to develop a tool scientists can use to link information about drugs, diseases and genes.

17 Sep 2014

State highlights: N.Y. sues drugmaker over Alzheimer's drug switch; Ariz. Republican resigns over Medicaid remarks

New York State's attorney general filed an antitrust lawsuit on Monday seeking to stop a pharmaceutical company from forcing patients with Alzheimer's disease to switch to a new version of a widely used drug. The lawsuit contends that the switch is designed to blunt competition from low-priced generic versions of the medication (Pollack, 9/15).

17 Sep 2014

New method helps reveal secret dance of proteins

Staying clear of diseases requires that the proteins in our cells cooperate with one another. But, it has been a well-guarded secret how tens of thousands of different proteins find the correct dancing partners as they degrade and build up the human body, brain and nervous system.

17 Sep 2014

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I).

17 Sep 2014

Pharmaceuticals News and Research

Mallinckrodt launches OptiSync system to help healthcare professionals manage radiology data

Yale University researchers study potential new treatment to reverse effects of pulmonary fibrosis

Elusys completes phase 3 clinical program of obiltoxaximab in healthy adult volunteers

Avalon Ventures, GSK jointly launch two new early-stage life science companies

C-Path renews grant to advance more effective drug treatments for TB

EYLEA Injection gets approval in Japan for treatment of myopic CNV

Demand for $84,000 hepatitis C drug slows

Soligenix awarded $24.7 million contract to advance development of Rivax vaccine

Regulus begins ATHENA study to monitor changes in renal function in Alport syndrome patients

PCI acquires Biotec Services International

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Disrupting cancer regulator MYC: an interview with Professor Kim Janda

Isis receives $4 million in milestone payment from Achaogen for initiation of plazomicin Phase 3 study

UMass Amherst doctoral student in chemistry receives USP's 2014-15 Global Fellowship Award

EnGeneIC receives award from Cancer Institute NSW for groundbreaking cancer research

Stago receives FDA approval for automated, highly sensitive D-dimer test

NIH awards grant to scientist to link drugs, genes and diseases

State highlights: N.Y. sues drugmaker over Alzheimer's drug switch; Ariz. Republican resigns over Medicaid remarks

New method helps reveal secret dance of proteins

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence